Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI Prior Auth & Step Therap…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Medicare Plus Blue Prior Authorization and Step Therapy Criteria — Pharmacy & Specialty Drugs (2026 Plan Year)

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists prior authorization and step therapy criteria for Medicare Plus Blue Group PPO and Prescription Blue Group PDP (2026), including product-specific coverage rules, prerequisite therapies, exclusions, age/diagnostic thresholds, documentation and reauthorization requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Michigan
    PolicyPrior authorization and step therapy criteria for pharmacy drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with required diagnostic proof and documentation of prior trials or positive clinical response as specified per product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    390document pages (total)
    multipleproducts listed with PA or ST criteria
    1 YEARtypical coverage duration values shown
    YEScombination therapy exclusions (explicit)
    ≥12example age restriction (Adbry)

    Product Coverage Criteria

    Adbry — Initial and reauthorization criteria

    Covered when ALL of the following are met:

    Adbry initial coverage: Patient is at least 12 years of age; diagnosis of moderate to severe atopic dermatitis; trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil; not used in combination with another biologic or targeted DMARD indicated for the same condition

    Reauthorization requires documentation of positive clinical response; for patients <100 kg who achieve response after 16 weeks, dosage limited to 300 mg every 4 weeks unless clinical rationale provided.

    Adbry reauthorization: Documentation of positive clinical response to therapy required for continued coverage

    Coverage duration: 1 year per product entry

    Braftovi — Indication-specific requirements

    Coverage for BRAF-mutated and other listed indications when the following condition-specific requirements are met:

    Policy Summary
    PayerBlue Cross Blue Shield - Michigan
    PolicyPrior authorization and step therapy criteria for pharmacy drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with required diagnostic proof and documentation of prior trials or positive clinical response as specified per product.
    SourceLink
    On This Page
    Product Coverage CriteriaInitial Authorization RequirementsReauthorization / Continuation RequirementsStep Therapy Requirements and TablesCode Tables and Key ValuesWhat Providers Must Submit / Watch ForBilling / Site of Care NotesProgram BackgroundKey Definitions
    Braftovi melanoma/solid tumors: Unresectable or metastatic melanoma with BRAF V600E or V600K mutation requiring combination regimens per indication (examples in the class include requirements to combine BRAF and MEK inhibitors)

    Prerequisite therapy may be required for some indications; coverage duration 1 year.

    Braftovi mCRC: Metastatic colorectal cancer with BRAF V600E mutation requires combination with cetuximab and fluorouracil‑based chemotherapy as specified

    See product entry for indication‑specific prior therapy requirements.

    Other BRAF V600E/V600K indications: Other unresectable/metastatic solid tumors with documented BRAF V600E or V600K mutation per FDA‑approved test, with combination use as indicated

    Prior trials and combination partners vary by tumor type.

    Auvelity — Step therapy requirement

    Covered when ALL of the following are met:

    Auvelity for major depressive disorder: Trial of bupropion AND trial of one other generic formulary antidepressant prior to initiation

    Coverage duration listed as lifetime for Auvelity.

    Tadalafil — Coverage and exclusion

    Covered when ALL of the following are met:

    Tadalafil for BPH: Diagnosis of benign prostatic hyperplasia (BPH) AND patient is not receiving concomitant nitrate therapy

    Coverage excluded if patient is receiving nitrate therapy; coverage duration 1 year.

    Fasenra: Initial and EGPA criteria

    Covered when ALL of the following are met:

    Fasenra — eosinophilic asthma (initial): Diagnosis of eosinophilic asthma AND blood eosinophil count ≥ 150 cells/μL at initiation AND inadequate control after trial of systemic corticosteroids or high‑dose inhaled corticosteroids plus a trial of an additional controller (leukotriene modifier OR LABA OR LAMA)eosinophils >= 150 cells/µL

    Applies to adults and children ≥6 years; reauthorization requires documentation of positive clinical response.

    Fasenra — EGPA: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND history or presence of asthma AND at least two typical EGPA clinical features (examples: histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity)2 clinical features

    Reauthorization requires documentation of positive clinical response.

    Schizophrenia - antipsychotic trial requirement

    Covered when ALL of the following are met:

    Schizophrenia — antipsychotic trial requirement: Trial of two generic formulary atypical antipsychotics (examples provided: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) prior to approval for listed antipsychotic productstrial of 2 generics

    Coverage duration commonly lifetime for these formulations.

    Adalimumab family: Indication-specific prerequisites

    Covered when ALL of the following are met:

    Adalimumab family — RA: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine)trial of 1 DMARD

    Reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for the same condition.

    Adalimumab family — JIA: Diagnosis of active polyarticular juvenile idiopathic arthritis AND trial of methotrexate or leflunomidetrial of 1 DMARD

    Apply pediatric criteria as specified.

    Adalimumab family — ankylosing spondylitis: Diagnosis of active ankylosing spondylitis AND trial of one NSAID prior to biologic therapytrial of 1 NSAID

    Reauthorization requires clinical response.

    Teriparatide: BMD and prior therapy requirements

    Covered when ALL of the following are met:

    Teriparatide (Forteo) initiation: Documentation of bone mineral density T‑score ≤ -2.5 AND trial of both Jubbonti or Stoboclo and either an oral bisphosphonate or, if intolerant, an IV bisphosphonate (coverage also provided if patient unable to be treated with listed alternatives)T-score <= -2.5

    Coverage duration 2 years; prerequisite Part D drug required per entry.

    Fruzaqla: mCRC prior therapy requirements

    Covered when ALL of the following are met:

    Fruzaqla — mCRC: Metastatic colorectal cancer: trial of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy AND trial of an anti‑VEGF therapy; for RAS wild‑type mCRC also trial of an anti‑EGFR therapytrial of specified chemotherapy and biologic therapies

    Coverage duration 1 year; prerequisite Part D drug required.

    Ulcerative colitis (UC) — coverage criteria

    Covered when ALL of the following are met:

    Ulcerative colitis (UC): Member has a diagnosis of moderately to severely active ulcerative colitis

    Reauthorization requires documentation of positive clinical response to therapy

    Hidradenitis suppurativa (HS) — coverage criteria

    Hidradenitis suppurativa (HS): Member has a diagnosis of moderate to severe hidradenitis suppurativa

    Reauthorization requires documentation of positive clinical response to therapy

    Non-infectious uveitis — coverage criteria

    Non-infectious uveitis: Member has diagnosis of non‑infectious uveitis classified as intermediate, posterior, or panuveitis

    Reauthorization requires documentation of positive clinical response to therapy

    Joenja (APDS) — coverage criteria

    Coverage for activated PI3K‑delta syndrome (APDS) requires ALL of the following:

    Joenja (APDS) coverage: 1) Diagnosis of APDS with an associated PI3Kδ mutation; 2) Documented variant in either PIK3CD or PIK3R1; 3) Documented symptoms associated with APDS such as nodal/extranodal lymphoproliferation, recurrent oto‑sino‑pulmonary infections, or organ dysfunction (e.g., lung, liver)

    Cannot be used in combination with an immunosuppressive medication; coverage duration 1 year.

    Kevzara — RA coverage criteria

    Kevzara coverage for rheumatoid arthritis requires ALL of the following:

    Kevzara RA coverage: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of two of the following: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia

    Cannot be used in combination with another biologic or targeted DMARD for same condition; reauthorization requires documentation of positive clinical response.

    Kineret — RA coverage criteria

    Kineret coverage for rheumatoid arthritis requires ALL of the following:

    Kineret RA coverage: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of two of the following: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia

    Cannot be used in combination with another biologic or targeted DMARD for same condition; reauthorization requires documentation of positive clinical response.

    Libervant — coverage criteria

    Libervant coverage: Trial of levetiracetam oral solution AND patient is unable to swallow tablets or capsules

    Coverage duration typically 1 year

    Lidocaine PTCH 5% / Lidocaine/prilocaine cream (BCC)

    Covered when ANY of the following are met:

    BCC coverage prerequisites: Patient has basal cell carcinoma AND either prior treatment with a hedgehog pathway inhibitor OR documented ineligibility for hedgehog pathway inhibitor treatment

    Coverage duration 1 year; prerequisite Part D drug may be required per entry.

    Liraglutide

    Covered when ANY of the following are met:

    Liraglutide for T2DM: Submission of medical records confirming diagnosis of type 2 diabetes mellitus OR lab evidence (A1c ≥6.5% OR fasting plasma glucose ≥126 mg/dL OR 2‑hour plasma glucose ≥200 mg/dL during OGTT)A1c >=6.5%; FPG >=126 mg/dL; 2‑hr PG >=200 mg/dL

    Excluded if used for weight loss only; coverage duration 1 year.

    Livtencity (post-transplant CMV)

    Covered when ALL of the following are met:

    Livtencity (post‑transplant CMV): Patient has post‑transplant CMV infection/disease AND trial of one of: ganciclovir, valganciclovir, cidofovir, or foscarnet

    Coverage duration 1 year; prerequisite Part D drug required.

    Lonsurf (metastatic colorectal cancer / gastric)

    Covered when ALL of the following are met:

    Lonsurf — mCRC/gastric: For metastatic colorectal cancer: used in combination with bevacizumab after trials of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and an anti‑VEGF; for gastric/GEJ adenocarcinoma: trial of at least two prior lines of chemotherapy as specified

    Coverage duration 1 year; prerequisite Part D drug required.

    Lumakras

    Covered when ALL of the following are met:

    Lumakras — NSCLC: KRAS G12C‑mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy

    For mCRC requires prior chemotherapy and combination with panitumumab as specified; coverage duration 1 year.

    Lybalvi (psychiatric therapy)

    Covered when ALL of the following are met:

    Lybalvi — psychiatric therapy: Trial of at least one specified generic antipsychotic (examples listed: aripiprazole, asenapine, haloperidol, quetiapine, risperidone, ziprasidone, etc.) prior to approval

    Coverage duration 1 year; prerequisite Part D drug required.

    Mekinist / Mekinist liquid / Mektovi

    BRAF V600E/V600K mutation‑positive tumors: covered when ALL of the following are met:

    Mekinist / Mektovi / related agents: Documented BRAF V600E or V600K mutation detected by an FDA‑approved test AND use in combination with the specified BRAF inhibitor (e.g., dabrafenib for Mekinist; encorafenib for Mektovi) or trial of vemurafenib + cobimetinib where required

    Liquid formulations require inability to swallow tablets; coverage duration 1 year; prerequisite Part D drug required.

    Mektovi — combination or prerequisite therapy

    Covered when ALL of the following are met:

    Mektovi — combination/prerequisite therapy: Unresectable or metastatic melanoma with BRAF V600E or V600K mutation requires prior trial of vemurafenib + cobimetinib used in combination OR combination with encorafenib as specified

    Coverage duration 1 year; prerequisite Part D drug required.

    Nucala — indication-specific coverage

    Nucala is covered when the indication‑specific criteria below are met:

    Nucala — eosinophilic asthma (EA): Diagnosis of eosinophilic asthma with eosinophil count ≥150 cells/µL at initiation AND inadequate control after trial of systemic corticosteroids or high‑dose inhaled corticosteroids plus a trial of an additional controller (leukotriene modifier OR LABA OR LAMA)eosinophils >=150 cells/µL

    Coverage duration 1 year; reauthorization requires documentation of positive clinical response.

    Nucala — EGPA: Diagnosis of EGPA AND presence of two typical clinical features of EGPA as listed in the product entry

    Reauthorization requires documentation of positive clinical response.

    Nucala — HES: Diagnosis of hypereosinophilic syndrome (HES) AND eosinophil count ≥1000 cells/µL at initiation AND stability on HES therapyeosinophils >=1000 cells/µL
    Nucala — CRSwNP: Diagnosis of chronic rhinosinusitis with nasal polyposis and recurring disease despite intranasal corticosteroids
    Nucala — COPD add‑on maintenance: Uncontrolled moderate‑to‑severe COPD AND either eosinophils ≥150 cells/µL at initiation OR ≥300 cells/µL within past 12 months AND patient receiving/continuing LABA + LAMA + ICS unless contraindicatedeosinophils >=150 or >=300 cells/µL

    Opfolda — diagnostic and failure criteria

    Opfolda is covered when ALL of the following are met:

    Opfolda criteria: Confirmation of diagnosis by serum assay showing decreased acid alpha‑glucosidase activity followed by genetic testing showing a GAA mutation AND presence of symptomatic manifestations (progressive muscle weakness, respiratory failure, frequent upper airway infections, orthopnea, sleep apnea, morning headaches) not limited to cardiac hypertrophy AND no improvement on current enzyme replacement therapy (ERT)

    Coverage duration 1 year; prerequisite Part D drug required.

    Acute Myeloid Leukemia — adult consolidation

    Covered when ALL of the following are met:

    AML consolidation (adult): Adult patient with acute myeloid leukemia who achieved first complete remission (CR) or CRi after intensive induction chemotherapy and is unable to complete intensive curative therapy

    Coverage duration: 1 year; prior authorization required.

    GAA deficiency disease — diagnostic confirmation

    Covered when ALL of the following are met:

    GAA deficiency disease: Confirmation by serum assay showing decreased acid alpha‑glucosidase activity followed by genetic testing confirming a GAA mutation AND symptomatic manifestations and no improvement on enzyme replacement therapy

    Coverage duration 1 year; prerequisite Part D drug required.

    Abatacept (Orencia) — indications and prerequisites

    Covered when ALL of the following are met:

    Abatacept (Orencia) — RA: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine)

    Reauthorization requires documentation of positive clinical response and Abatacept not used in combination with other immunosuppressives (e.g., JAK inhibitors, biologic DMARDs).

    Abatacept — polyarticular JIA: Diagnosis of active polyarticular juvenile idiopathic arthritis AND trial of methotrexate or leflunomide

    Posaconazole DR — prophylaxis and treatment

    Covered when ANY of the following are met:

    Posaconazole DR — prophylaxis: Patient at high risk for invasive fungal infection (HSCT with GVHD or hematologic malignancy with prolonged neutropenia) or requiring secondary prophylaxis AND trial of two of: fluconazole, itraconazole, or voriconazole

    Coverage duration: 6 months; prerequisite Part D drug required.

    Posaconazole DR — treatment: Used for treatment of invasive fungal infections due to Aspergillus or Candida AND trial of two of fluconazole, itraconazole, or voriconazole as appropriate

    Coverage per product entry; prior authorization required.

    Praluent — lipid disorders

    Praluent initiation and reauthorization covered when the following diagnostic and treatment history criteria are met:

    Praluent — ASCVD/Primary HLD initiation: Patient with ASCVD or primary hyperlipidemia who, while on high‑intensity statin within the prior 120 days (or statin‑intolerant), has LDL >=55 mg/dL with ASCVD or >70 mg/dL without ASCVD AND trials of atorvastatin and rosuvastatin or documented statin intoleranceLDL thresholds as stated

    Coverage duration 3 years; prerequisite Part D drug required.

    Praluent — HeFH/HoFH: Clinical or genetic confirmation per product entry (HeFH/HoFH) with appropriate prior lipid‑lowering therapy

    Reauthorization requires continued LDL reduction while on therapy.

    Eltrombopag — thrombocytopenia indications

    Covered when ANY of the following indication‑specific criteria are met:

    Eltrombopag — ITP: Persistent or chronic immune thrombocytopenia with baseline platelet count <30,000/mcL AND trial of corticosteroids, IVIG, or splenectomy prior to eltrombopagBaseline platelets <30,000/mcL

    Coverage duration 1 year; prerequisite Part D drug required.

    Eltrombopag — thrombocytopenia with chronic HCV: Baseline platelet count <75,000/mcLBaseline platelets <75,000/mcL
    Eltrombopag — severe aplastic anemia: Baseline platelet count <30,000/mcLBaseline platelets <30,000/mcL

    Jubbonti / Stoboclo

    Covered when ALL prerequisite and exclusion conditions are satisfied:

    Jubbonti / Stoboclo coverage: Trial of an oral bisphosphonate OR, if intolerant, an IV bisphosphonate; coverage also provided if patient unable to be treated with both oral and IV bisphosphonates

    Coverage duration 3 years; coverage not provided for hypocalcemia per product entry.

    Eltrombopag olamine

    Covered when ANY of the following are met:

    Eltrombopag olamine — indications: Persistent/chronic ITP with baseline platelets <30,000 mcl OR thrombocytopenia with chronic hepatitis C with baseline platelets <75,000 mcl OR severe aplastic anemia with baseline platelets <30,000 mcl

    Coverage duration 1 year; requires prior trials of corticosteroids, immunoglobulins, or splenectomy for ITP.

    Retevmo

    Covered when ANY of the following are met:

    Retevmo — RET‑altered tumors: Adult NSCLC with RET fusion detected by FDA‑approved test OR adult/pediatric MTC with RET mutation requiring systemic therapy; some thyroid indications require prior radioactive iodine if appropriate; patients with RET fusion solid tumors must have progressed on or after prior systemic therapy

    Coverage duration 1 year; prerequisite Part D drug required.

    Rezdiffra (NASH/MASH)

    Rezdiffra is covered when ALL of the following initial criteria are met:

    Rezdiffra initial coverage: Diagnosis of noncirrhotic NASH or MASH AND advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based noninvasive assessment AND trial of semaglutide prior to coverageliver fibrosis stage F2 to F3

    Coverage duration 1 year; renewal requires no progression to cirrhosis and demonstration of histologic/imaging improvement or clinical benefit.

    Rinvoq (upadacitinib)

    Rinvoq (oral and liquid) coverage requires ALL of the following depending on indication:

    Rinvoq — prohibition: Cannot be used in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine) or with another biologic or targeted DMARD indicated for the same condition

    Reauthorization requires documentation of positive clinical response and avoidance of prohibited combinations.

    Rinvoq — rheumatologic indications: Indication‑specific diagnosis (RA, PsA, AS, UC, nonradiographic axial spondyloarthritis) AND required prior trials (e.g., DMARDs, NSAIDs, TNF inhibitors) as specified per indication

    Reauthorization requires documentation of positive clinical response; prerequisite Part D drug required for many indications.

    Rinvoq — atopic dermatitis: Diagnosis of moderate to severe atopic dermatitis AND trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil

    Rivfloza

    Covered when ALL of the following are met:

    Rivfloza (RPH1): Diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by genetic testing of the AGXT mutation

    Exclusions: history of kidney or liver transplant and combination use with Oxlumo; coverage duration 1 year.

    Rybrevant

    Covered when ANY of the following are met:

    Rybrevant — EGFR exon 20 insertion: NSCLC with EGFR exon 20 insertion mutation AND disease progression on or after platinum‑based chemotherapy

    Other EGFR mutation settings have specific combination requirements per product entry; coverage duration 1 year.

    Rydapt

    Covered when ALL of the following are met:

    Rydapt — FLT3+ AML: Newly diagnosed FLT3 mutation‑positive acute myeloid leukemia when used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation

    Coverage duration 1 year.

    Secuado

    Covered when ANY of the following are met:

    Secuado (asenapine patch) — schizophrenia: Trial of sublingual asenapine tablet OR documented difficulty with oral or ODT formulations prior to covering the transdermal patch

    Coverage duration: lifetime.

    Multiple myeloma — initial coverage criteria

    Covered when ALL of the following are met:

    Multiple myeloma — initial coverage: Treatment with at least 2 prior therapies including lenalidomide and a proteasome inhibitor; relapsed/refractory disease requires 1–3 prior lines as specified

    Coverage duration 1 year; prerequisite Part D drug required.

    Tafinlar — indication-specific criteria

    Tafinlar (capsule and liquid) covered when ALL of the following are met:

    Tafinlar — indication/formulation requirements: Unresectable or metastatic melanoma with BRAF V600E or V600K mutation requires prior trial of vemurafenib + cobimetinib and, where specified, combination use with trametinib; liquid formulation coverage requires inability to swallow capsules

    Coverage duration 1 year; prerequisite Part D drug required.

    Tagrisso — EGFR mutation indications

    Tagrisso is covered for the following EGFR mutation‑defined settings when the listed prerequisites are met:

    Tagrisso — EGFR indications: EGFR exon 19 deletion or exon 21 L858R mutation‑positive NSCLC used as adjuvant post‑resection, as first‑line metastatic therapy, or first‑line locally advanced/metastatic in combination with pemetrexed + platinum chemotherapy; EGFR T790M‑positive NSCLC requires progression on/after an EGFR TKI

    Coverage duration 1 year; prerequisite Part D drug required.

    General product coverage statements

    Per‑product coverage statements summarize whether coverage is indication‑specific or applies to all medically‑accepted indications. Many products listed below have additional indication‑dependent requirements (see individual entries).

    Product summary: Entry indicates whether coverage is for all medically‑accepted indications or limited to specified indications; where limited, indication‑specific diagnostic, prior therapy, and documentation requirements apply

    Refer to each product's detailed criteria for prerequisites, exclusions, and reauthorization rules.

    Tocilizumab

    Tocilizumab coverage for listed rheumatologic indications requires ALL of the following:

    Tocilizumab — RA: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of two of: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia

    Cannot be used in combination with another biologic/targeted DMARD for same condition; reauthorization requires documentation of positive clinical response; coverage duration 1 year.

    Tocilizumab — JIA/SJIA/GCA: Diagnosis and indication‑specific prior trial requirements as listed (e.g., JIA: trial of methotrexate or leflunomide; SJIA: trial of NSAID, systemic glucocorticoid, or methotrexate; GCA: diagnosis of giant cell arteritis)

    Reauthorization requires documentation of positive clinical response.

    Tetrabenazine

    Notable limitations and documentation requirements:

    Tetrabenazine limitations: Not covered for patients with hepatic impairment OR actively suicidal/untreated or inadequately treated depression OR taking MAO inhibitors or reserpine; documentation of CYP2D6 genotype required for doses >50 mg/day

    Coverage duration 1 year where indicated.

    Tymlos

    Tymlos is covered when ALL of the following are met:

    Tymlos initiation: Documentation of bone mineral density T‑score ≤ -2.5 AND trial of Jubbonti or Stoboclo AND either an oral bisphosphonate or, if intolerant, an IV bisphosphonate (coverage provided if unable to be treated with listed alternatives)T-score ≤ -2.5

    Coverage duration 2 years; prerequisite Part D drug required.

    Ubrelvy

    Covered when ALL of the following are met:

    Ubrelvy — acute migraine: Trial of at least two generic triptans (e.g., sumatriptan, rizatriptan) unless triptan therapy is contraindicated, not tolerated, or clinically inappropriate

    Coverage duration 1 year; prerequisite Part D drug required.

    Verquvo

    Verquvo is covered when ALL of the following clinical criteria are met:

    Verquvo criteria: Diagnosis of chronic heart failure NYHA class II–IV AND left ventricular ejection fraction (LVEF) <45% AND either prior hospitalization for heart failure within prior 6 months OR outpatient IV diuretic treatment within prior 3 months; must be taken with at least two specified guideline‑directed therapies unless contraindicatedLVEF <45%

    Coverage duration 1 year; prerequisite Part D drug not required per entry.

    Voquezna

    Voquezna (Dual/Triple Pak) is covered when ALL of the following are met:

    Voquezna H. pylori treatment: Documented diagnosis of Helicobacter pylori infection AND trial of a guideline‑recommended generic first‑line regimen (clarithromycin triple therapy OR bismuth quadruple therapy) prior to coverage

    Coverage duration 1 year; prerequisite Part D drug required.

    Oncology product prerequisite therapy examples

    Selected oncology and specialty product prerequisite therapy examples (coverage requires meeting ALL listed product‑specific prerequisites):

    Oncology prerequisites (examples): Coverage for many oncology indications requires prior systemic therapies or specific combination partners (examples include prior platinum‑based chemotherapy for certain NSCLC agents; prior endocrine or chemotherapy for breast cancer agents; prior abiraterone 250 mg trial for select prostate cancer indications)

    Refer to each product entry for the exact prior therapy and sequencing requirements.

    Vigabatrin

    Covered when ALL product‑specific criteria are satisfied:

    Vigabatrin coverage: Coverage per indicated uses with prior authorization; follow product‑specific requirements

    Coverage duration 1 year where indicated.

    Voquezna

    Covered when ALL of the following are met:

    Voquezna Dual/Triple Pak (H. pylori): Diagnosis of H. pylori infection AND trial of a guideline‑recommended generic first‑line regimen (clarithromycin triple therapy OR bismuth quadruple therapy)

    Coverage duration 1 year; prerequisite Part D drug required.

    Vosevi

    Covered when ALL of the following are met:

    Vosevi coverage: Coverage applied consistent with current AASLD/IDSA guidance for indicated hepatitis C scenarios

    Criteria follow guideline‑recommended sequencing of antiviral therapy.

    Voydeya (extravascular hemolysis in PNH)

    Voydeya is covered when ALL of the following are met:

    Voydeya — EVH in PNH: Clinically significant extravascular hemolysis (EVH) due to PNH with hemoglobin ≤ 9.5 g/dL AND absolute reticulocyte count ≥ 120 × 10^9/LHgb <=9.5 g/dL; retic >=120x10^9/L

    Coverage duration 1 year; combination use only with Soliris or Ultomiris as specified.

    Welireg

    Covered when ANY of the following indication‑specific criteria are met:

    Welireg indications: Covered for indicated diagnoses including pheochromocytoma/paraganglioma and VHL disease; advanced RCC requires prior PD‑1/PD‑L1 inhibitor and a VEGF‑TKI

    Prerequisite Part D drug required where noted; coverage duration 1 year.

    Winrevair (PAH)

    Winrevair is covered when ALL of the following are met:

    Winrevair (PAH): Diagnosis of pulmonary arterial hypertension AND trial of both: generic sildenafil or tadalafil AND generic bosentan or ambrisentan prior to approval

    Coverage duration 1 year; prerequisite Part D drug required.

    Xatmep

    Covered when ALL of the following are met:

    Xatmep indications: Indication‑specific diagnostic requirements (e.g., ALL: diagnosis of acute lymphoblastic leukemia; PJIA initial: active polyarticular JIA with trial/failure/intolerance to one NSAID) and age restrictions where applicable

    Coverage duration 1 year; prerequisite Part D drug required.

    Xeljanz (tofacitinib)

    Xeljanz (tofacitinib) coverage requires ALL of the following per indication:

    Xeljanz coverage conditions: Diagnosis‑specific prior trials (e.g., RA: trial of one DMARD; JIA: trial of methotrexate or leflunomide) AND inadequate response/intolerance to one or more TNF inhibitors when required; not used in combination with potent immunosuppressants or another biologic/targeted DMARD

    Reauthorization requires documentation of positive clinical response; coverage duration 1 year; prerequisite Part D drug required for many indications.

    Xifaxan TABS 550MG

    Xifaxan 550 mg coverage is indication‑specific and requires prior trials:

    Xifaxan — indications: Hepatic encephalopathy: trial of lactulose prior to Xifaxan; IBS‑D: trial of loperamide, dicyclomine, or diphenoxylate/atropine; recurrent C. diff: trial of vancomycin

    Coverage duration 1 year; prerequisite Part D drug required.

    Xdemvy (demodex blepharitis)

    Covered when ALL of the following are met:

    Xdemvy (demodex blepharitis): Confirmation of demodex blepharitis via presence of collarettes on slit lamp exam

    Coverage duration 1 year; prerequisite Part D drug not required.

    Sodium oxybate

    Covered when ALL product‑specific criteria are satisfied; notable exclusions apply:

    Sodium oxybate coverage: Diagnosis of narcolepsy with cataplexy or excessive daytime sleepiness AND if age ≥18 a trial of armodafinil and Sunosi; not covered for patients taking sedative hypnotics or with succinic semialdehyde dehydrogenase deficiency

    Coverage duration 1 year; prerequisite Part D drug required.

    Yonsa / Zarxio

    Covered when ALL of the following are met:

    Yonsa coverage: Trial of abiraterone 250 mg as specified in product entry prior to coverage

    Prerequisite Part D drug required; coverage duration 1 year.

    Zarxio coverage: Covered for medically‑accepted indications; AML coverage requires prior induction or consolidation chemotherapy

    Coverage duration 1 year; prerequisite Part D drug not required.

    This section summarizes product-specific coverage criteria and general rules that apply across listed drugs. Many products require prior authorization and coverage is provided only when the product-specific clinical criteria are met (see individual product entries). Reauthorization typically requires documentation of a positive clinical response to therapy. Examples: Adbry (dupilumab-bxxx) is covered for patients ≥12 years with moderate–severe atopic dermatitis after a trial and failure of one listed topical or systemic therapy; dosing for patients weighing <100 kg who achieve response at 16 weeks is limited to 300 mg every 4 weeks unless clinical rationale is provided (chunk 2).

    Biologic and targeted immunomodulators often carry a combination-use prohibition: coverage is not provided when used concurrently with another biologic or targeted DMARD indicated for the same condition (examples: Adbry, Fasenra, Nucala, many abatacept/tofa/Rinvoq entries) — such combination use may trigger denial (chunks 2, 41, 101, 111).

    Many products include indication-specific prerequisites and measurable thresholds. Examples include eosinophil-count requirements for anti‑eosinophil agents (e.g., EA initiation commonly requires ≥ 150 cells/μL), baseline diagnostic confirmation for genetic or enzyme-deficiency disorders (e.g., Rivfloza: AGXT genetic testing), and laboratory or imaging thresholds for metabolic/hepatic or bone conditions (see Nucala, Rivfloza, Praluent and Tymlos entries) (chunks 41, 139, 101, 126).

    Initial coverage commonly requires documented trials of specified alternatives (step therapy) or failure/intolerance to lower-tier agents prior to approval; for some psychiatric and neurologic agents lifetime coverage is contingent on documented comparator trials (e.g., antidepressant and antipsychotic comparator lists; oral risperidone before long‑acting risperidone formulations) (chunks 216, 218, 234).

    Documentation expectations: providers must submit the clinical data specified in each product entry (examples: baseline T25FW for dalfampridine, IgE and allergy testing for Xolair, genetic or enzyme testing for Opfolda and Rivfloza, BMD T‑score for teriparatide/Tymlos). Absence of required documentation or failure to meet prerequisite trial requirements may result in denial (chunks 24, 194, 109, 44, 247).

    Coverage durations are product-specific but commonly set to 1 YEAR; select products have different durations (e.g., Praluent 3 years, certain osteoporosis agents 2–3 years, lifetime for some long‑acting injectables) — confirm the duration in the product entry before authorizing (chunks 2, 124, 44, 216).

    Tadalafil (oral tablets) is not covered when the patient is receiving concomitant nitrate therapy; requests for BPH treatment must document the diagnosis and the absence of nitrate therapy. Coverage duration is typically 1 year per the product entry (chunk 19).

    Budesonide ER is specifically excluded for the indication of maintenance of remission in ulcerative colitis; the product entry states that coverage will not be provided for maintenance of remission in UC (chunk 14).

    Two distinct exclusions are highlighted: tadalafil coverage is not provided when patients are receiving nitrates; dalfampridine ER is excluded for patients who are wheelchair‑bound or who become wheelchair‑bound. For dalfampridine, a baseline timed 25‑foot walk (T25FW) must be submitted prior to initiation and reauthorization requires documentation of stability or improvement (chunks 19, 24).

    Fasenra (benralizumab) must not be used in combination with another biologic or targeted DMARD indicated for the same condition. Indication‑specific criteria apply (e.g., for eosinophilic asthma an eosinophil count ≥ 150 cells/μL at initiation and prior controller/systemic steroid trial), and reauthorization requires documentation of clinical response (chunk 41).

    Products indicated or used solely for weight loss are excluded. For agents that have diabetes indications (e.g., liraglutide), coverage is allowed when used for type 2 diabetes mellitus with supporting documentation (medical records or labs such as A1c ≥ 6.5%, FPG ≥ 126 mg/dL, or 2‑hour OGTT ≥ 200 mg/dL); however, requests solely for weight loss will be denied as not medically necessary (chunks 49, 75).

    Kevzara (sarilumab) may not be used in combination with another biologic or targeted DMARD indicated for the same condition. For rheumatoid arthritis coverage requires diagnosis of moderately to severely active RA and a trial of two specified alternatives (examples include ENBREL, adalimumab biosimilars, RINVOQ, XELJANZ/XR, or ORENCIA); reauthorization requires documentation of positive clinical response (chunk 67).

    Some immunomodulators and immunosuppressive biologics carry combination‑use prohibitions: abatacept/Orencia and other agents cannot be used concurrently with other immunosuppressives (e.g., JAK inhibitors or biologic DMARDs) — such use is an exclusion and may trigger denial. Kevzara and Kineret entries likewise prohibit concurrent use with another biologic or targeted DMARD for the same condition (chunks 111, 67, 68).

    Joenja coverage for activated PI3K‑delta syndrome (APDS) requires genetic confirmation (documented variant in PIK3CD or PIK3R1) plus clinical manifestations consistent with APDS (e.g., nodal/extranodal lymphoproliferation, recurrent oto‑sino‑pulmonary infections, organ dysfunction). Joenja cannot be used in combination with an immunosuppressive medication for APDS (chunk 64).

    Liraglutide is covered for treatment of type 2 diabetes when diagnostic documentation is provided (A1c ≥ 6.5% or FPG ≥ 126 mg/dL or 2‑hr OGTT ≥ 200 mg/dL), but it is explicitly excluded if prescribed solely for weight loss (chunk 75). More generally, the policy excludes use for weight loss only for several specified products (chunk 49).

    Nucala (mepolizumab) is not to be used in combination with another biologic or targeted DMARD indicated for the same condition. Coverage is indication‑specific with eosinophil thresholds (e.g., eosinophilic asthma initiation usually ≥ 150 cells/μL, HES ≥ 1000 cells/μL) and reauthorization requires documentation of positive clinical response (chunks 101, 103).

    Requests that propose combination use of biologics, JAK inhibitors, or other potent immunosuppressants with another biologic/targeted DMARD for the same indication are excluded across multiple product entries; several agents explicitly prohibit such concurrent use (examples include abatacept/Orencia, Xeljanz/tofacitinib, and Xolair) and these prohibitions may lead to denial if documented (chunks 111, 191, 194).

    Certain products include explicit non‑coverage for hypocalcemia. The product entries state that coverage is not provided for hypocalcemia for the specified products; refer to the product line for the full list and context (chunk 126).

    Rivfloza (lumasiran) coverage requires genetic confirmation of primary hyperoxaluria type 1 (AGXT mutation). Coverage will not be provided for patients with a history of kidney or liver transplant, and combination use with Oxlumo is prohibited (chunk 139).

    Initial Authorization Requirements

    Reauthorization / Continuation Requirements

    Adbry — Reauthorization

    Adbry reauthorization

    Adbry reauthorization criteria: Reauthorization requires documentation of positive clinical response to therapy

    Refer to initial dosing limitations for patients <100 kg (300 mg q4w after 16 weeks if responsive) and do not combine with other biologic/targeted DMARDs for same condition.

    Reauthorization/documented response

    Reauthorization requirements

    General reauthorization: For many biologic and targeted DMARD products, reauthorization requires documentation of positive clinical response to therapydocumentation of response

    Applies to Fasenra, adalimumab family, Tocilizumab, Nucala, and others as specified; coverage durations commonly 1 year.

    Reauthorization requirements

    Reauthorization rules

    Reauthorization — general rule: Documentation of positive clinical response to therapy is required for reauthorization for applicable indications

    Applies across product classes where noted in product entries.

    Nucala reauthorization

    For all Nucala indications:

    Nucala reauthorization: Reauthorization requires documentation of positive clinical response to therapy for the specific Nucala indication

    Coverage duration typically 1 year.

    Zilbrysq continuation

    Continuation requirements for Zilbrysq

    Zilbrysq continuation: Patient is currently receiving and will continue to receive a stable regimen AND documentation of prior adequate courses of immunosuppressive therapy (at least 12 weeks) unless contraindicated or not tolerated

    Coverage duration 1 year; prerequisite Part D drug required.

    Step Therapy Requirements and Tables

    ProductStep requirement
    Auvelity
    Trial of bupropion and one other generic formulary antidepressant required prior to coverage
    Product / groupStep requirement
    Topical agents (examples)
    Trial of at least one generic topical steroid (or generic Protopic or generic Elidel) required prior to coverage
    ProductStep requirement
    Arcalyst (recurrent pericarditis)
    Trial of a nonsteroidal anti-inflammatory drug (NSAID) in combination with colchicine required prior to coverage
    Scope / examplesTypical requirement
    Antipsychotics (schizophrenia examples)
    Trial of two generic formulary atypical antipsychotics required (examples: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
    Requirement categoryPolicy
    Trial of specified alternative(s)
    Many products require trial and documented failure or intolerance to specified generic or formulary alternatives prior to approval (product-specific list)
    ProductRequired prior agents
    Kevzara (RA)
    Trial of two of: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia required prior to coverage
    Context / exampleStep requirement
    Oncology examples (selected)
    Many oncology indications require trial of at least one prior systemic therapy or specified prior chemotherapies (examples: Lumakras requires ≥1 prior systemic therapy; Lonsurf requires prior fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy and anti‑VEGF therapy)
    General ruleRequirement
    Must have trial and documented failure/ineligibility
    Products frequently require documented trial and failure of specified prior agents or documented ineligibility/intolerance before approval; details are product-specific
    Requirement typeDocumentation expected
    Prior trial or contraindication/intolerance
    Approval requires documentation of prior trial or clinical contraindication/intolerance to listed comparator agents (examples vary by product)
    Area / drug classStep therapy example
    Antifungals / DMARDs / Statins (examples)
    Posaconazole prophylaxis requires trial with two of fluconazole, itraconazole, or voriconazole; DMARDs required prior to Orencia; Praluent requires trial of high-intensity statin (or documented intolerance)
    Multiple productsPrior trial requirement (examples)
    Various specialty products (examples)
    Jubbonti/Stoboclo require trial of an oral bisphosphonate (or IV if intolerant); Retevmo may require prior radioactive iodine when appropriate; Rezdiffra requires trial of semaglutide; Tolvaptan requires trials of furosemide, demeclocycline, or fluid restriction
    ScenarioStep requirement
    Lower-tier or specified agent required first
    Some branded products require trial of lower-tier generics or specific comparators (e.g., Spritam requires trial of 2 generic anticonvulsants; Sunosi requires trial of armodafinil)
    Product / indicationStep requirement
    Ubrelvy (acute migraine)
    Trial of at least two generic triptans required unless triptan therapy is contraindicated, not tolerated, or clinically inappropriate
    ProductRequired prior regimen
    Voquezna (H. pylori dual/triple Pak)
    Trial of a guideline-recommended generic first-line H. pylori regimen (clarithromycin triple therapy or bismuth quadruple therapy) required prior to Voquezna
    ProductStep therapy examples by indication
    Xifaxan (various indications)
    Hepatic encephalopathy: trial of lactulose required; Recurrent C. diff: trial of vancomycin required; IBS-D: trial of loperamide, dicyclomine, or diphenoxylate/atropine required
    ProductStep requirement
    Winrevair (PAH)
    Trial of both: (1) generic sildenafil or tadalafil AND (2) generic bosentan or ambrisentan required prior to coverage
    ProductStep requirement
    Trintellix (and Exxua products)
    Trial of at least two specified generic antidepressants required prior to coverage
    ProductPrerequisite
    Abilify Asimtufii / Abilify Maintena
    Trial of oral aripiprazole required prior to coverage
    Comparator requirementPolicy
    Generic comparator failure (general)
    Many products require documented failure or intolerance to specified generic comparator drugs before approval (provider must document trials or contraindications)
    ProductStep requirement
    Paliperidone palmitate (long-acting injectables)
    Trial of once-monthly paliperidone palmitate for ≥4 months OR every-three-month paliperidone palmitate for at least one 3‑month cycle required prior to coverage
    Situation / product examplesRequired prior trial or documentation
    Risperidone long‑acting / Perseris / Rasuvo / Rytary / Farxiga/Jardiance / Febuxostat (examples)
    Prior trial of the specified generic/comparator agent or documented contraindication/intolerance is required before approval (e.g., oral risperidone before long‑acting risperidone; generic injectable methotrexate before Rasuvo; generic ER carbidopa/levodopa before Rytary; dapagliflozin trial before Farxiga/Jardiance; allopurinol trial before febuxostat)

    Code Tables and Key Values

    Products Affected (sample)mixed
    Braftovi CAPS 75MGProduct listing as provided
    Drug references in excerptNDC|brand
    DABRAFENIBMekinist SOLR DABRAFENIB (reference to combination use with dabrafenib)
    Pancreaze unit sizesNDC
    149900UNITPancreaze CPEP 149900UNIT
    37000UNITPancreaze CPEP 37000UNIT
    97300UNITPancreaze CPEP 97300UNIT
    15200UNITPancreaze CPEP 15200UNIT
    2600UNITPancreaze CPEP 2600UNIT
    8800UNITPancreaze CPEP 8800UNIT
    24600UNITPancreaze CPEP 24600UNIT
    4200UNITPancreaze CPEP 4200UNIT
    14200UNITPancreaze CPEP 14200UNIT
    61500UNITPancreaze CPEP 61500UNIT
    1–10 of 18
    1/2
    Adbry dosing and restrictions
    Adbry weight-based dosing limitFor patients weighing <100 kg who achieve positive clinical response after 16 weeks, dosage is limited to 300 mg every 4 weeks unless clinical rationale is provided
    Age restriction (Adbry)Patient must be at least 12 years of age
    Combination exclusionCannot be used in combination with another biologic or targeted DMARD indicated for the same condition
    Eosinophil count thresholds
    EA initiation threshold>= 150 cells/µL at initiation
    COPD add-on maintenance threshold>= 300 cells/µL (or >=150 cells/µL current) — COPD requires concurrent LABA + LAMA + ICS
    HES initiation threshold (related entry)>= 1000 cells/µL at initiation (for HES)
    Age and weight thresholds (Dupixent examples)
    Dupixent age thresholdsAtopic dermatitis (AD): ≥6 months; Eosinophilic asthma (EA) and corticosteroid-dependent asthma (CDA): ≥6 years; CRSwNP/CSU: ≥12 years; EOE: ≥1 year; PN: ≥18 years
    Dupixent EOE weight thresholdPatient must weigh at least 15 kilograms for EOE
    General prerequisite therapies (examples)AD requires trial/failure of high-potency topical steroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine or mycophenolate mofetil
    Eosinophil count at initiation
    Eosinophil count at initiation (EA)>= 150 cells per microliter
    Documentation requirementEosinophil count must be documented at treatment initiation
    Related controller trial requirementFailure to maintain control after systemic or high-dose inhaled corticosteroids plus an additional controller is required for biologic initiation
    Bone mineral density T-score threshold
    BMD T-score threshold (Forteo/Tymlos)T-score ≤ -2.5 (2.5 standard deviations or more below the mean)
    Documentation requirementRequire documentation of bone mineral density showing T-score ≤ -2.5
    Prior therapy requirement (osteoporosis agents)Coverage requires trial of Jubbonti or Stoboclo and either an oral bisphosphonate (or IV if intolerant)
    A1c diagnostic threshold
    A1c diagnostic threshold>= 6.5%
    Use in diabetes documentationSubmit medical records confirming T2DM or lab evidence (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hr PG ≥200 mg/dL)
    Exclusion noteExcluded if used solely for weight loss
    Fasting plasma glucose diagnostic threshold
    Fasting plasma glucose (FPG) threshold>= 126 mg/dL
    ContextFPG can be used as laboratory evidence to confirm type 2 diabetes when submitting documentation
    Related thresholdsA1c ≥6.5% or 2‑hour OGTT ≥200 mg/dL are alternative diagnostic criteria
    2-hour OGTT diagnostic threshold
    2-hour OGTT diagnostic threshold>= 200 mg/dL
    Use case2‑hour plasma glucose during OGTT may be submitted as diagnostic evidence for T2DM
    Alternate diagnosticsA1c ≥6.5% or FPG ≥126 mg/dL also acceptable
    Eosinophil counts (Nucala/HES/EA thresholds)
    Eosinophilic asthma initiation threshold>= 150 cells/µL at initiation
    COPD add-on maintenance>=150 cells/µL current OR >=300 cells/µL within past 12 months; patient must be on LABA + LAMA + ICS
    HES initiation threshold>= 1000 cells/µL at initiation (for HES)
    LDL thresholds for Praluent initiation
    LDL threshold with ASCVDLDL >= 55 mg/dL while on high-intensity statin within last 120 days
    LDL threshold without ASCVDLDL > 70 mg/dL while on high-intensity statin within last 120 days
    Statin documentationPatient must have had ≥12 weeks of high-intensity statin or documented statin intolerance and trials of atorvastatin and rosuvastatin
    Baseline platelet counts
    Baseline platelet count — ITP and severe aplastic anemia< 30,000/mcL
    Baseline platelet count — thrombocytopenia with chronic hepatitis C< 75,000/mcL
    Prior therapy for ITPRequires trial of corticosteroids, immunoglobulins, or splenectomy prior to eltrombopag
    Liver fibrosis stage (Rezdiffra)
    Liver fibrosis stage requiredF2 to F3 (advanced fibrosis) verified by FibroScan or other imaging-based non-invasive assessment
    Prerequisite therapyTrial of semaglutide required prior to coverage
    Renewal requirementRenewal requires no progression to cirrhosis and histologic or imaging-based improvement or clinical benefit
    BMD (Tymlos)
    BMD threshold (Tymlos / Forteo)T-score ≤ -2.5
    DocumentationRequire documentation of bone mineral density T-score ≤ -2.5
    Prior therapy requirementCoverage requires trial of Jubbonti or Stoboclo and an oral bisphosphonate (or IV if intolerant)
    CYP2D6 genotype threshold (tetrabenazine)
    CYP2D6 genotype requirementDocumentation of CYP2D6 genotype required for tetrabenazine doses > 50 mg/day
    Exclusion criteriaNot covered for patients with hepatic impairment, active suicidal ideation or untreated/inadequately treated depression, or concurrent MAO inhibitors/reserpine
    Coverage durationOne year (as listed)
    Left ventricular ejection fraction (Verquvo)
    Left ventricular ejection fraction (LVEF)LVEF < 45% required for Verquvo coverage
    Additional HF criteriaNYHA class II-IV plus prior HF hospitalization within 6 months or outpatient IV diuretic within 3 months also required
    Therapy contextMust be taken with at least two guideline-directed therapies unless contraindicated
    Hemoglobin/reticulocyte criteria (Voydeya)
    Hemoglobin threshold (Voydeya EVH in PNH)Hemoglobin <= 9.5 g/dL
    Reticulocyte thresholdAbsolute reticulocyte count >= 120 × 10^9/L
    Combination therapy noteCoverage requires combination use with Soliris or Ultomiris only
    IgE thresholds for Xolair allergic asthma
    IgE threshold — ages ≥12 (allergic asthma)IgE > 30 and < 700 IU/mL for age ≥12
    IgE threshold — ages 6–12IgE > 30 and < 1300 IU/mL for ages 6–12
    CRSwNP upper limitFor CRSwNP IgE up to 1500 IU/mL at initiation
    Recent insulin claim requirement
    Recent insulin claim requirementA claim for an insulin product within the last 180 days is required for coverage
    Coverage durationCoverage duration noted as 1 year when requirement met
    Documentation noteProvide claim record as part of prior authorization submission

    What Providers Must Submit / Watch For

    Prior Authorization

    Submit prior authorization per product

    Prior authorization is required for each listed product; verify the drug on the formulary and submit PA that meets the product-specific clinical and administrative criteria before coverage is provided.

    • Each product entry includes indications, exclusions, age/prescriber limits, coverage duration, and prerequisite therapy requirements.
    • Providers can contact the pharmacy help desk or the customer service number on the member ID card to request PA/ST.
    Prior Authorization

    Confirm PA identification and meet criteria

    Drugs identified with (PA) or (ST) in the formulary must meet the documented clinical and/or administrative criteria prior to coverage; many PAs specify a standard coverage duration (commonly one year) and reauthorization requires documentation of positive clinical response.

    • Coverage duration is commonly 1 year unless otherwise noted (some products list lifetime or multi-year durations).
    • Reauthorization generally requires documentation of positive clinical response.
    Documentation Required

    Provide reauthorization and response documentation

    Prior authorization approvals and reauthorizations commonly require documentation of positive clinical response; coverage durations are typically one year unless otherwise specified in the product entry.

    • Reauthorization for Adbry and many biologics requires documentation of positive clinical response.
    • Coverage durations are specified per product (e.g., 1 year typical; some products list lifetime or multi‑year durations).
    Step Therapy

    Document two triptan trials before dihydroergotamine

    For dihydroergotamine mesylate prior authorization, document a trial of two formulary triptans — one oral and one non‑oral (e.g., nasal or injectable) — before approval.

    • PA requires trial of two triptans on the formulary: one oral and one non‑oral.
    Prior Authorization

    Document indication‑specific prerequisite trials (Dupixent/Nucala examples)

    For dupilumab and related biologics (e.g., Dupixent/Adbry), document indication‑specific prerequisite trials and thresholds: e.g., for atopic dermatitis a trial and failure of one: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine or mycophenolate mofetil; for eosinophilic asthma include eosinophil count thresholds (≥150 cells/µL) and prior controller/systemic steroid trials per the product entry.

    • Adbry AD: trial and failure of one specified topical/systemic therapy required; reauthorization requires positive clinical response and dosing limits for patients <100 kg.
    • Dupixent: EOE requires trial of PPI or topical esophageal corticosteroid; EA requires eosinophils ≥150 cells/µL and controller failure.
    • Nucala/related entries also specify eosinophil thresholds and prior therapy trials where applicable.
    Prior Authorization

    Submit PA for Part D specialty products per entry

    Part D specialty products listed require prior authorization; coverage durations, prerequisite therapy, and documentation requirements vary by product and indication — follow the specific product entry.

    • Many specialty agents require PA with one‑year duration and indication‑specific prerequisites.
    • Some oncology and specialty agents require prior systemic therapies or combination regimens as specified.
    Prior Authorization

    Meet diagnosis‑specific PA criteria (UC/HS/uveitis)

    Coverage for specified indications (e.g., UC, hidradenitis suppurativa, non‑infectious uveitis) requires meeting diagnosis‑specific criteria and documentation of disease severity; reauthorization requires demonstrated clinical benefit.

    • UC: diagnosis of moderately to severely active disease required.
    • HS: diagnosis of moderate to severe HS required.
    • Non‑infectious uveitis: diagnosis classified as intermediate, posterior, or panuveitis required.
    Prior Authorization

    Provide Lenvima indication and combination documentation

    Lenvima requests must meet the dose‑ and indication‑specific PA criteria; certain RCC indications require combination use (e.g., with pembrolizumab) or prior anti‑angiogenic therapy as specified.

    • Follow the Prior Authorization Criteria section for the specified Lenvima daily dose.
    • RCC first‑line: combination with pembrolizumab required; other RCC settings may require prior anti‑angiogenic therapy or everolimus.
    Prior Authorization

    Document Lenvima combination/prior therapy

    For some Lenvima indications, verify required combination or prior therapies in the request (e.g., pembrolizumab for RCC first‑line or everolimus following prior anti‑angiogenic therapy).

    • Document the specific combination partner or prior anti‑angiogenic therapy per the labeled indication before approval.
    Documentation Required

    Include general PA elements and prior therapy evidence

    Ensure submitted PA requests include the general prior authorization elements: specific indication, required prior therapy trials or contraindications, prescriber/age restrictions, and intended duration (commonly 1 year).

    • Some products also require a prerequisite Part D drug — confirm and document prior treatments.
    • Reauthorization ordinarily requires documentation of positive clinical response.
    Prior Authorization

    Document Lynparza prior platinum chemotherapy

    Lynparza coverage requires documentation of prior platinum‑based chemotherapy for BRCA‑mutated advanced ovarian/fallopian tube/primary peritoneal cancer and other indication‑specific prior therapies per the product entry.

    • Document prior platinum chemotherapy and any other required prior regimens as noted in the Lynparza criteria before PA approval.
    Documentation Required

    Show Mekinist combination and swallowing rationale

    Mekinist (tablet and liquid) approvals require combination use with dabrafenib for most BRAF V600E/V600K indications; liquid formulation requires documentation of inability to swallow tablets.

    • For BRAF‑mutant melanoma/NSCLC/ATC and other specified tumors, document combination therapy with dabrafenib.
    • If requesting liquid Mekinist, include documentation the patient cannot swallow tablets.
    Prior Authorization

    Provide Mektovi combination/prior therapy details

    Mektovi prior authorization requires documentation of indicated combination or prior trial(s) for melanoma or NSCLC BRAF V600E/V600K indications; coverage duration is typically one year.

    • Document prior trial of vemurafenib + cobimetinib or combination with encorafenib per the Mektovi product criteria.
    Documentation Required

    Document Nucala indication‑specific criteria and labs

    Nucala PA approvals must document indication‑specific criteria (e.g., eosinophil thresholds and required prior controller/systemic steroid trials for eosinophilic asthma; EGPA diagnostic features; HES eosinophil ≥1000 cells/µL and stability on therapy); reauthorization requires documentation of clinical response.

    • EA: eosinophils ≥150 cells/µL at initiation and failure to maintain control after systemic or high‑dose inhaled steroids plus another controller.
    • EGPA: diagnosis plus two typical clinical features per the Nucala criteria.
    • HES: eosinophil ≥1000 cells/µL at initiation and stability on HES therapy.
    Documentation Required

    Attach product‑specific prerequisite documentation

    Refer to product PA summaries for Movantik, Octreotide, and Opfolda — include indication‑specific prerequisites (e.g., opioid stability for Movantik; trial of bromocriptine for acromegaly with octreotide; enzyme assay and confirmatory genetic testing for Opfolda) when submitting PA.

    • Opfolda: include decreased acid alpha‑glucosidase assay result and GAA gene mutation plus symptomatic manifestations and lack of improvement on ERT.
    • Movantik/Octreotide: include required prior therapy evidence as noted in each product entry.
    Documentation Required

    Document AML consolidation remission and inability to complete curative therapy

    For adult AML consolidation prior authorization, document that the patient achieved CR/CRi after intensive induction chemotherapy and is unable to complete intensive curative therapy; coverage duration is one year.

    • Include clinical documentation of CR/CRi status and the inability to complete intensive curative therapy in the PA submission.
    Prior Authorization

    Document prior azole trials for posaconazole DR

    Posaconazole DR prior authorization for prophylaxis requires trial of two of fluconazole, itraconazole, or voriconazole; for specified prophylaxis/treatment uses include the required prior antifungal trials and note the 6‑month coverage duration.

    • Prophylaxis: document trials of two specified azoles when indicated.
    • Coverage duration for prophylaxis is 6 months.
    Documentation Required

    Provide LDL and statin trial documentation for Praluent

    Praluent PA requires diagnostic and treatment history documentation: LDL thresholds while on high‑intensity statin (e.g., ≥55 mg/dL with ASCVD or >70 mg/dL without ASCVD) and evidence of prior high‑intensity statin use or statin intolerance plus trials of atorvastatin and rosuvastatin.

    • Provide LDL while on high‑intensity statin and record of at least 12 weeks of high‑intensity statin therapy or documented statin intolerance.
    • Include trials of atorvastatin and rosuvastatin per the Praluent criteria.
    Documentation Required

    Document bisphosphonate trial/intolerance for Jubbonti/Stoboclo

    Jubbonti/Stoboclo PA requires documentation of trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate (or inability to be treated with both); coverage duration is 3 years.

    • Attach records showing trial of an oral bisphosphonate or documentation of intolerance to oral bisphosphonates and reasons for IV therapy.
    Documentation Required

    Submit baseline platelet counts and prior therapy for eltrombopag

    For eltrombopag PA, include baseline platelet counts and prior therapy trials: ITP baseline platelets <30,000/mcL and prior corticosteroids/IVIG or splenectomy as applicable; thrombocytopenia with chronic hepatitis C requires baseline platelets <75,000/mcL.

    • Provide baseline platelet count and prior therapy history (corticosteroids, IVIG, splenectomy) as specified in the eltrombopag criteria.
    Documentation Required

    Attach RET molecular testing for Retevmo

    Retevmo PA requires documentation of RET gene fusion or RET mutation detected by an FDA‑approved test for the indicated NSCLC/thyroid/solid tumor uses; include prior radioactive iodine trial when appropriate.

    • Attach molecular testing results confirming RET fusion/mutation via an FDA‑approved test.
    • For thyroid indications, document trial/failure of radioactive iodine if appropriate.
    Documentation Required

    Provide fibrosis staging and semaglutide trial for Rezdiffra

    Rezdiffra coverage requires verification of noncirrhotic NASH/MASH with advanced fibrosis (F2‑F3) by FibroScan or other imaging‑based noninvasive assessment and documentation of a trial of semaglutide prior to approval; reauthorization criteria require no progression to cirrhosis and objective improvement/stability.

    • Submit FibroScan or equivalent imaging evidence of fibrosis stage F2–F3 and documentation of semaglutide trial.
    • For renewal, include imaging/histologic or clinical evidence per the renewal criteria.
    Prior Authorization

    Include Rinvoq prior therapy and prohibition documentation

    Rinvoq (oral and liquid) PA requires indication‑specific prerequisites (e.g., trials of DMARDs, NSAIDs, TNF inhibitors where applicable) and documentation that the drug will not be used with potent immunosuppressants or another biologic/targeted DMARD; reauthorization requires positive clinical response.

    • For RA/PsA/AS/UC: document prior DMARD/NSAID/TNF inhibitor trials per the Rinvoq criteria.
    • Confirm the patient is not receiving Rinvoq with a potent immunosuppressant or another biologic.
    Documentation Required

    Document prior platinum chemotherapy for Rybrevant requests

    Rybrevant PA for NSCLC with EGFR exon 20 insertion requires documentation of disease progression on or after platinum‑based chemotherapy; include mutation and prior therapy details.

    • Attach evidence of EGFR exon 20 insertion and prior platinum‑based chemotherapy with documentation of progression.
    Prior Authorization

    Confirm Rydapt combination with standard induction/consolidation

    Rydapt PA for newly diagnosed FLT3‑mutated AML requires that the drug be used in combination with standard cytarabine + daunorubicin induction and cytarabine consolidation; include regimen details in the PA submission.

    • Document that Rydapt will be given in combination with standard induction and consolidation chemotherapy as specified.
    Note
    Documentation Required

    Provide documented prior myeloma therapies

    For products treating multiple myeloma, document prior therapy history showing at least two prior therapies including lenalidomide and a proteasome inhibitor (relapsed/refractory criteria and coverage duration are specified in the product entry).

    • Include prior therapy lines and agents (lenalidomide and a proteasome inhibitor) per the multiple myeloma prerequisite criteria.
    Documentation Required

    Document trial of sublingual asenapine or inability to use oral forms

    Secuado (asenapine patch) coverage requires documentation of a trial of sublingual asenapine OR documented inability to use oral/ODT formulations; include this trial or swallowing/intolerance evidence.

    • Attach records showing trial of sublingual asenapine or documented difficulty with oral/ODT formulations supporting patch use.
    Step Therapy

    Document two prior alternatives for Kevzara/Kineret and exclude combination use

    Kevzara and Kineret PA/step requirements for RA require trials of two specified alternatives (e.g., Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia); document these prior trials and that the agent will not be combined with another biologic/targeted DMARD.

    • Include records of trials of two listed alternatives.
    • Confirm no concurrent use with another biologic/targeted DMARD for the same condition.
    Note
    Note
    Prior Authorization

    Document prior systemic therapies for Trodelvy (TNBC)

    Trodelvy coverage for triple‑negative breast cancer requires prior use of two or more systemic therapies (one for metastatic disease); document the prior systemic therapy history per the Trodelvy criteria.

    • Include prior systemic therapy names, lines of therapy, and which was used for metastatic disease.
    Prior Authorization

    Submit indication documentation for Vigabatrin PA

    Vigabatrin requests require prior authorization consistent with the listed indications and usually a one‑year coverage duration; include indication‑specific documentation per the product entry.

    • Attach documentation supporting the indicated use and any required prior trials as described.
    Step Therapy

    Document H. pylori diagnosis and first‑line regimen trial for Voquezna

    Voquezna Dual/Triple Pak for H. pylori requires documented H. pylori infection and a trial of a guideline‑recommended generic first‑line regimen (clarithromycin triple or bismuth quadruple therapy) prior to coverage; include the first‑line regimen trial evidence.

    • Document positive H. pylori diagnosis and prior trial of a guideline‑recommended first‑line regimen (clarithromycin triple or bismuth quadruple).
    Documentation Required

    Provide IgE/allergy testing and prior therapy evidence for Xolair PA

    Xolair prior authorization requires documentation of IgE level and allergy testing (positive skin test or in‑vitro reactivity) for allergic asthma, and other indication‑specific diagnostic and prior therapy documentation; reauthorization requires documented clinical response.

    • For allergic asthma: include IgE level in the specified range and evidence of positive skin or in‑vitro reactivity to a perennial aeroallergen.
    • For CRSwNP/CSU: include the diagnostic criteria and prior therapy trials as specified.
    Step Therapy

    Document oral aripiprazole trial before Abilify injectable approvals

    Require trial of oral aripiprazole before approving Abilify Asimtufii or Abilify Maintena; include documentation of the oral trial (or intolerance) with the PA request.

    • Coverage duration for these products is lifetime pending the required trial documentation.
    Note
    Step Therapy

    Document two generic antidepressant trials for Trintellix

    Trintellix (and Exxua/Exxua Titration Pack) requires documentation of trials of at least two listed generic antidepressants prior to coverage; include medication names and trial durations in the PA request.

    • List the two (or more) generic antidepressants tried (from the enumerated list) and evidence of inadequate response or intolerance.
    Documentation Required

    Attach required prior oncology therapy evidence

    Many oncology/specialty agents require documentation of specific prior therapies (e.g., abiraterone 250 mg tablet trial for selected prostate cancer uses); include exact prior therapy and dosing evidence as specified in the product entry.

    • For prostate cancer products note the required abiraterone 250 mg tablet trial where indicated.
    • For oncology agents generally, document prior systemic lines, specific agents, and combination regimens per criteria.
    Denial Risk

    Provide two generic antidepressant trials or risk denial

    Antidepressant comparator requirement: submit documentation of trials of at least two specified generic antidepressants (from the listed set) before PA approval for indicated products; failure to document these trials may result in denial.

    • Include drug names, treatment dates, and reason for failure/intolerance for each trial.
    Step Therapy

    Document antipsychotic comparator trial to support PA

    Antipsychotic comparator requirement: prior authorization requires trial of at least one listed generic typical/atypical antipsychotic before coverage of certain products; document the trial to avoid denial.

    • List the specific antipsychotic(s) tried and the treatment outcome or intolerance.
    Note
    Note
    Step Therapy

    Document prior paliperidone palmitate injectable regimen

    For paliperidone palmitate long‑acting injectables, document trial of once‑monthly paliperidone palmitate for ≥4 months or an every‑three‑month cycle for at least one three‑month cycle prior to approval.

    • Provide treatment dates and formulation details of the prior paliperidone palmitate regimen.
    Step Therapy

    Document trial of oral paliperidone/risperidone

    Prior authorization for oral paliperidone/risperidone formulations requires documentation of a prior trial of oral paliperidone or oral risperidone where specified; include trial details to support coverage.

    • Include medication name, dosing, dates, and reason for failure/intolerance.
    Prior Authorization

    Document Zenpep trial/intolerance for pancreatic enzyme PA

    Pancreatic enzyme product PA requires documentation of trial or intolerance to Zenpep (comparator) before approval for the listed products; include prior trial details.

    • Provide documentation of trial duration and outcomes or intolerance to Zenpep.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Billing / Site of Care Notes

    Note

    Submit site‑of‑care information (Part B vs D)

    Coverage determinations between Medicare Part B and Part D may depend on the use and setting of the drug; submit information describing the drug use and setting when requested to determine appropriate coverage.

    Program Background

    The prior authorization and step‑therapy program is intended to ensure clinically appropriate, evidence‑based, and cost‑effective use of specialty and other high‑cost drugs for Medicare Plus Blue members. Providers should submit required clinical documentation (diagnosis, prior therapy trials, relevant laboratory or genetic test results, baseline measures such as T25FW where required) as specified in each product entry. Many products include indication‑specific prerequisites, age or weight minimums, and reauthorization requirements that document a positive clinical response; typical coverage durations are listed in the product entries (commonly 1 year). For drugs that may be covered under Medicare Part B or Part D, the setting and use may affect coverage determination and should be included with the request.

    Key Definitions

    PA definition
    Prior Authorization (PA)A process where clinical and/or administrative criteria must be met before coverage is provided for a drug
    PurposeEnsures clinically appropriate and cost-effective drug therapy per Pharmacy & Therapeutics Committee recommendations
    IdentificationDrugs subject to PA are identified in the formulary with (PA)
    ST definition
    Step Therapy (ST)A requirement that patients try one or more formulary drugs before coverage of a requested agent
    ApplicationST requirements and examples are specified per product entry in the formulary
    ExceptionsMay be waived if contraindicated or clinically inappropriate
    Reauthorization definition
    Reauthorization requirementReauthorization generally requires documentation of positive clinical response to therapy for all indications
    Typical coverage durationCoverage duration commonly one year; some products list different durations (e.g., 2 or 3 years, lifetime)
    Applies to biologics/DMARDsMany biologic and targeted DMARD entries explicitly require documented clinical response for reauthorization
    Eosinophilic asthma criteria (definition)
    Eosinophilic asthma definitionDiagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at initiation AND failure to maintain control after systemic or high-dose inhaled corticosteroids plus trial of an additional controller
    Required trialsMust have trial of systemic corticosteroids or high-dose ICS and one additional controller (leukotriene modifier, LABA, or LAMA)
    Age contextApplies to adults and children as specified (e.g., often ≥12 years) per product entry
    EGPA criteria (definition)
    EGPA coverage definitionDiagnosis of EGPA plus history or presence of asthma and at least two typical EGPA clinical features (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity)
    ReauthorizationReauthorization requires documentation of positive clinical response
    Associated lab/pathologyHistopathologic evidence may be used as one of the qualifying EGPA features
    APDS (definition)
    APDS definitionActivated PI3K-delta syndrome (APDS) coverage requires diagnosis with associated PI3Kδ mutation and documented variant in PIK3CD or PIK3R1 plus symptoms (e.g., lymphoproliferation, recurrent infections, organ dysfunction)
    Combination restrictionCannot be used in combination with an immunosuppressive medication for APDS treatment
    DocumentationGenetic and clinical documentation required to support coverage
    Mutation-specific coverage (definition)
    Mutation-specific coverage definitionCoverage for several oncology drugs contingent on documented tumor mutation status (e.g., BRAF V600E/V600K, KRAS G12C, BRCA) detected by an FDA-approved test
    Test requirementMolecular testing by FDA-approved or equivalent test is required where specified
    Indication examplesExamples include Mekinist, Retevmo, Lumakras, Lynparza entries with mutation-specific criteria
    EGPA criteria (alt)
    EGPA (Nucala) definitionEGPA: diagnosis plus two typical clinical criteria required for Nucala coverage
    Examples of criteriaHistopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity
    ReauthorizationPositive clinical response documentation required for reauthorization
    HES threshold
    HES threshold definitionHypereosinophilic syndrome (HES) requires eosinophil count of at least 1000 cells/µL at initiation and stability on HES therapy
    Stability requirementPatient must be stable on HES therapy (oral corticosteroids, immunosuppressive or cytotoxic therapy)
    Product exampleNucala entry specifies these HES requirements
    HeFH / HoFH / ASCVD / Primary HLD definitions
    HeFH / HoFH / ASCVD / Primary HLD definitionsClinical definitions include LDL thresholds, family history, genetic confirmation, and prior treatment trials as specified for Praluent initiation
    LDL specificsLDL >=55 mg/dL with ASCVD or LDL >70 mg/dL without ASCVD while on high-intensity statin (within 120 days)
    Genetic/clinical confirmationHeFH/HoFH may require genetic confirmation or clinical criteria such as very high untreated LDL or tendon xanthomas
    RET fusion / mutation definition
    RET fusion / mutation definitionGenomic alterations in the RET gene detected by an FDA-approved test required for Retevmo coverage in specified indications
    Indication scopeIncludes RET-fusion NSCLC and RET-mutated MTC and thyroid cancers where testing is required
    Prerequisite therapySome thyroid indications require prior radioactive iodine when appropriate
    NASH / MASH with advanced fibrosis definition
    NASH / MASH with advanced fibrosis definitionNonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stage F2 to F3 verified by FibroScan or other imaging-based non-invasive assessment
    Semaglutide prerequisiteTrial of semaglutide required prior to Rezdiffra coverage
    Renewal criteriaRenewal requires no progression to cirrhosis and histologic/imaging improvement or clinical benefit
    Genetic confirmation (ACVR1)
    Genetic confirmation (ACVR1)Genetic testing confirming an ACVR1 mutation is required to support coverage for FOP indication
    DocumentationSubmit genetic testing results as part of prior authorization
    Coverage durationTypically one year as listed
    NYHA class II-IV
    NYHA class II-IV requirementDocumented chronic heart failure NYHA class II-IV required for Verquvo coverage
    Additional LVEF criterionLeft ventricular ejection fraction <45% required
    Recent event requirementPrior hospitalization for heart failure within 6 months or outpatient IV diuretic within 3 months required
    CYP2D6 genotype
    CYP2D6 genotype requirementPatient's CYP2D6 metabolizer status required to guide tetrabenazine dosing above 50 mg/day
    Exclusion contextTetrabenazine not covered for hepatic impairment, active suicidal ideation/untreated depression, or concurrent MAO inhibitors/reserpine
    DocumentationGenotype documentation must be submitted for doses >50 mg/day
    AChR antibody positive myasthenia gravis
    AChR antibody positive myasthenia gravis definitionMyasthenia gravis confirmed by positive anti-AChR antibody test plus one confirmatory test (edrophonium, response to cholinesterase inhibitors, or electrophysiologic evidence)
    Prior therapy requirementPrevious treatment courses of at least 12 weeks with listed immunosuppressants required unless contraindicated
    ExclusionsHistory of thymectomy within 12 months, current thymoma, or other thymus neoplasms exclude coverage
    Paliperidone palmitate definition
    Paliperidone palmitate definitionPaliperidone palmitate extended-release injectable suspension (monthly or every-three-month formulations)
    Trial requirement contextPrior trial of specified paliperidone palmitate regimens required for related long-acting products
    Coverage durationCoverage duration commonly listed as lifetime for these products
    Pancreatic enzyme products definition
    Pancreatic enzyme products definitionPancreatic enzyme replacement therapy formulations (e.g., Zenpep, Pancreaze) with listed unit sizes
    Comparator requirementPrior trial or intolerance to Zenpep is required for coverage of listed pancreatic enzyme products
    Coverage durationCoverage duration often listed as lifetime when comparator requirement met